anti-doping is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-06-18. Where a claim depends on a specific study, the study is described rather than over-claimed.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
== Venom == The venom of Bothrops moojeni has hemolytic and proteolytic action. The venom contains a wide variety of enzymes, such as acidic phospholipase, base A phospholipase, metalloproteinases, serine proteinases, L-amino acid oxidase, and a myotoxin phospholipase A2. The myotoxin phospholipase A2 causes necrosis in muscle fibers, releasing creatine kinase. Symptoms may include intense local pain, edema, muscular necrosis. The venom has an anticoagulant effect on the blood, makes the blood uncoagulable, causes severe hemorrhage and strokes. Moojenactivase, a procoagulant metalloproteinase is capable to induce DIC with a high toxic potency, characterized by prolongation of Prothrombin and activated partial thromboplastin time, consumption of fibrinogen and the plasma coagulation factors like Factor X and II, and thrombocytopenia, it also caused Intravascular hemolysis. The venom has a lethal dose of 0.205 mg / kg for horses. The average yield for an adult female is 335 mg, 63 mg for newborns. Specimens from Minas Gerais, Brazil have been reported to yield 118 mg. Specimens from Argentina have a yield of 248.0 ± 37 mg. A serine protease was determined by de novo mass spectrometry-based sequencing.
== Appearances == The Headcrab debuted in Half-Life (1998) as an enemy that attacks protagonist Gordon Freeman and other surviving humans by leaping at them and biting them. Headcrabs first appear when a portal is opened, sending various interdimensional beings into the game's world and sending the Black Mesa lab into chaos. Throughout the game, the player encounters bodies with Headcrabs on their head, some of which becoming animated and attacking living people. In the sequel, Half-Life 2, the Headcrab and Headcrab Zombies return in a similar capacity. Headcrabs can be found in various environments, and the main antagonists, the Combine, who have taken control of the world post-invasion, have been attacking civilian and resistance groups by shooting rockets with Headcrabs in them to infect the population. Other Headcrabs appear, including a fast one and a poison one, the latter of which can put Gordon in serious danger if bitten. The character Isaac Kleiner manages to debeak a Headcrab, keeping it as a pet called Lamarr. Headcrabs also appear in Half-Life: Alyx, a virtual reality game. Fast-moving Headcrabs and Zombies were originally considered for inclusion, but were removed due to tests finding that they moved too fast for players to properly react. Outside of the Half-Life series, the Headcrab makes multiple cameo appearances. Multiple games, such as Vindictus and the Steam releases of Phantasy Star Online 2, Death Stranding, and Fall Guys featured accessories based on the Headcrab.
If the drug is delivered through a mucous membrane in the mouth, the residence time is short because saliva washes it away. Strategies to increase this residence time include bioadhesive polymers, gums, lozenges and dry powders.
Eliot, Ezra Pound, William Carlos Williams, Basil Bunting, Gertrude Stein, Francis Picabia, Yvor Winters; was daughter of Hungarian Jewish tailor, Sigmund Felix Lowy, who had moved to London to evade persistent antisemitism in Budapest, and Christian, English mother. Michael Hamburger OBE poet and translator Anna Mendelssohn (born Anna Mendleson, 1948 – 15 November 2009), who wrote under the name Grace Lake, was prolific writer, poet, artist and political activist with The Angry Brigade; was inspired by the Paris student risings in May 1968, and became political radical in Britain; later studied poetry at St Edmund's College, Cambridge, devoting her life to poetry and art; became opposed to technology, disliking judgments based on rationality in favour of those based on artistic judgment. Vivian de Sola Pinto, poet John Rodker, poet and publisher Isaac Rosenberg, war poet Leon Rosselson, radical singer, songwriter and children's book author. Siegfried Sassoon, writer and WW1 poet, of Iraqi Jewish Mizrahi Jewish origin. Henry Shukman (born 1962 in Oxford, Oxfordshire); poet and writer; father was historian Harold Shukman; brother is BBC News reporter David Shukman. Jon Silkin, poet Stephen Spender (28 February 1909 – 16 July 1995); poet, novelist and essayist whose work concentrated on themes of social injustice and the class struggle; son of Harold Spender (22 June 1864 – 15 April 1926), Liberal Party politician, author, journalist and lecturer of German Jewish ancestry.
Sources: en.wikipedia.org
The nitrogen of the ethanamine (and no other atoms of the side chain) is included in a cyclic structure. The phenyl ring of the benzyl system is substituted by an alkoxy group containing three carbon atoms. The 5- position of the benzimidazole system is substituted by a nitro group.
This is particularly so considering that bicalutamide increases circulating testosterone levels, and by extension gonadal testosterone production, by up to two-fold in males, and that only a small fraction of normal intratesticular testosterone levels, and by extension androgen action, appears to be necessary to maintain spermatogenesis. Bicalutamide monotherapy at 50 mg/day causes no or clinically unimportant Leydig cell hyperplasia. In contrast to bicalutamide and other pure antiandrogens or NSAAs, antigonadotropic antiandrogens suppress gonadotropin secretion, which in turn diminishes testosterone production by the testes as well as the maintenance of the testes by FSH, resulting in atrophy and loss of their function. As such, bicalutamide and other NSAAs may uniquely have the potential to preserve testicular function and spermatogenesis and thus male fertility relative to alternative therapies. In accordance with this notion, a study found that prolonged, high-dose bicalutamide treatment had minimal effects on fertility in male rats. However, another study found that low-dose bicalutamide administration resulted in testicular atrophy and reduced the germ cell count in the testes of male rats by almost 50%, though the rate of successful fertilization and pregnancy following mating was not assessed. Additional studies found that bicalutamide decreased testes weights, altered testes histology, and decreased sperm count in male rats. Yet another study found that bicalutamide has no effect on testes weights or spermatogenesis in male rats.
== History == Eucalyptus was founded in 2019 by Tim Doyle, Charlie Gearside, Benny Kleist, and Alexey Mitko. The company launched Pilot, a men's health telehealth service, as its first brand. Subsequent brands included Juniper (weight management), Software (dermatology), and Kin (fertility and reproductive health). In June 2023, Eucalyptus acquired the digital assets of Jenny Craig Australia after the brand entered voluntary administration. The company raised A$8 million in Series A funding in May 2020, $30 million in Series B in July 2021, and $60 million in Series C in January 2022. A 2023 funding round raised an additional A$50 million. The company was valued at $560 million in April 2023. In February 2026, Eucalyptus was acquired by Hims & Hers Health in a transaction valued at up to US$1.15 billion. The transaction was completed in June 2026.
Sources: en.wikipedia.org
=== Density === The alkali metals all have the same crystal structure (body-centred cubic) and thus the only relevant factors are the number of atoms that can fit into a certain volume and the mass of one of the atoms, since density is defined as mass per unit volume. The first factor depends on the volume of the atom and thus the atomic radius, which increases going down the group; thus, the volume of an alkali metal atom increases going down the group. The mass of an alkali metal atom also increases going down the group. Thus, the trend for the densities of the alkali metals depends on their atomic weights and atomic radii; if figures for these two factors are known, the ratios between the densities of the alkali metals can then be calculated. The resultant trend is that the densities of the alkali metals increase down the table, with an exception at potassium. Due to having the lowest atomic weight and the largest atomic radius of all the elements in their periods, the alkali metals are the least dense metals in the periodic table. Lithium, sodium, and potassium are the only three metals in the periodic table that are less dense than water: in fact, lithium is the least dense known solid at room temperature.
=== Therapeutic potential === Further research into myostatin and the myostatin gene may lead to therapies for muscular dystrophy. The idea is to introduce substances that block myostatin. A monoclonal antibody specific to myostatin increases muscle mass in mice and monkeys. A two-week treatment of normal mice with soluble activin type IIB receptor, a molecule that is normally attached to cells and binds to myostatin, leads to a significantly increased muscle mass (up to 60%). It is thought that binding of myostatin to the soluble activin receptor prevents it from interacting with the cell-bound receptors. In September 2020 scientists reported that suppressing activin type 2 receptors-signalling proteins myostatin and activin A via activin A/myostatin inhibitor ACVR2B – tested preliminarily in humans in the form of ACE-031 in the early 2010s – can protect against both muscle and bone loss in mice. The mice were sent to the International Space Station and could largely maintain their muscle weights – about twice those of wild type due to genetic engineering for targeted deletion of the myostatin gene – under microgravity. Treating progeric mice with soluble activin receptor type IIB before the onset of premature ageing signs appear to protects against muscle loss and delay age related signs in other organs. It remains unclear as to whether long-term treatment of muscular dystrophy with myostatin inhibitors is beneficial, as the depletion of muscle stem cells could worsen the disease later on. As of 2012, no myostatin-inhibiting drugs for humans are on the market.
Stroma (from Ancient Greek στρῶμα (strôma) 'layer, bed, bed covering') is the part of a tissue or organ with a structural or connective role. It is made up of all the parts without specific functions of the organ - for example, connective tissue, blood vessels, ducts, etc. The other part, the parenchyma, consists of the cells that perform the function of the tissue or organ. There are multiple ways of classifying tissues: one classification scheme is based on tissue functions and another analyzes their cellular components. Stromal tissue falls into the "functional" class that contributes to the body's support and movement. The cells which make up stroma tissues serve as a matrix in which the other cells are embedded. Stroma is made of various types of stromal cells. Examples of stroma include:
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.